Directors’ Report 5. CSL Performance and Shareholder Returns 2 T he 2016 Annual Return on Invested Capital figure includes the gain on acquisition of Novartis’ global influenza vaccine business of US$176.1m. The opening share price on 1 July 2017 was A$138.03. The Total Shareholder Return outcome at 30 June 2022 was -4.60%. The Total Dividends per Share is the actual total dividends paid within the financial year. 5.1 Financial Performance from 2016 to 2022 The following graphs2 summarise key financial performance over the past seven financial years. We have disclosed over a seven year period to align with our ROIC LTI performance measurement period. Cash Inflow FromOperating Activities (millions USD) Annual Return on Invested Capital Closing Share Price (dollars) – AUD Total Shareholder Return (12month %) – AUD Total Dividends Per Share (cents USD) 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 2022 2021 2020 2019 2018 2017 2016 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 2022 2021 2020 2019 2018 2017 2016 Net Profit After Tax/ Earnings Per Share (USD) Net Profit After Tax (millions) – USD Earnings Per Share (cents) – USD Closing Share Price (at 30 June AUD)/ Total Shareholder Return 0 100 200 300 400 2022 2021 2020 2019 2018 2017 2016 -20.0% 0.0% 20.0% 40.0% 60.0% 0 500 1,000 1,500 2,000 2,500 2022 2021 2020 2019 2018 2017 2016 0% 120% 240% 360% 480% 600% 0 50 100 150 200 250 2022 2021 2020 2019 2018 2017 2016 CSL Limited Annual Report 2021/22 80
RkJQdWJsaXNoZXIy MjE2NDg3